Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells

Annals of the New York Academy of Sciences

Volumn 1044, Issue , 2005, Pages 168-177

  Balabanov, Stefan ^a   Appel, Silke ^a   Kanz, Lothar ^a   Brossart, Peter ^a   Brümmendorf, Tim H ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bcr Abl; Dendritic cells; Hematopoiesis; Imatinib; Stem cells

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; PROTEIN TYROSINE KINASE;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; LEUKEMIA; NEUTROPENIA; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; T LYMPHOCYTE; THROMBOCYTOPENIA;

EID: 22044440489     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1349.022     Document Type: Conference Paper

References (72)

1. DRUKER, B.J. & N.B. LYDON. 2000. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest 105: 3-7.
2. DRUKER, B.J., M. TALPAZ, D.J. RESTA, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
3. DRUKER, B.J., S. TAMURA, E. BUCHDUNGER, et al 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566.
4. DEININGER, M.W., J.M. GOLDMAN, N. LYDON, et al. 1997. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698.
5. GAMBACORTI-PASSERINI, C., P. LE COUTRE, L. MOLOGNI, et al. 1997. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23: 380-394.
6. BUCHDUNGER, E., C.L. CIOFFI, N. LAW, et al. 2000. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295: 139-145.
7. HEINRICH, M.C., D.J. GRIFFITH, B.J. DRUKER, et al. 2000. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925-932.
8. OKUDA, K., E. WEISBERG, D.G. GILLILAND, et al. 2001. ARG tyrosine kinase activity is inhibited by STI571. Blood 97: 2440-2448.
9. CARROLL, M., S. OHNO-JONES, S. TAMURA, et al. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952.
10. KANTARJIAN, H., C. SAWYERS, A. HOCHHAUS, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346: 645-652.
11. SAWYERS, C.L., A. HOCHHAUS, E. FELDMAN, et al. 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539.
12. TALPAZ, M., R.T. SILVER, B.J. DRUKER, et al. 2002. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928-1937.
13. DRUKER, B.J., C.L. SAWYERS, H. KANTARJIAN, et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038-1042.
14. OTTMANN, O.G., B.J. DRUKER, C.L. SAWYERS, et al. 2002. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100: 1965-1971.
15. APPERLEY, J.F., M. GARDEMBAS, J.V. MELO, et al. 2002. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347: 481-487.
16. HEINRICH, M.C., C.D. BLANKE, B.J. DRUKER, et al. 2002. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20: 1692-1703.
17. PASSEGUE, E., C.H. JAMIESON, L.E. AILLES, et al. 2003. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. USA 100 (Suppl. 1): 11842-11849.
18. PETZER, A.L., C.J. EAVES, M.J. BARNETT, et al. 1997. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 90: 64-69.
19. BRUMMENDORF, T.H., W. DRAGOWSKA, J.M.J.M. ZIJLMANS, et al. 1998. Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells. J. Exp. Med. 188: 1117-1124.
20. GLIMM, H. & C.J. EAVES. 1999. Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture. Blood 94: 2161-2168.
21. SU, R.J., X.B. ZHANG, K. LI, et al. 2002. Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances long-term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. Br. J. Haematol. 117: 735-746.
22. DRUKER, B.J. 2003. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40: 50-58.
23. O'BRIEN, S.G., F. GUILHOT, R.A. LARSON, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348: 994-1004.
24. DEMETRI, G.D., M. VON MEHREN, C.D. BLANKE, et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347: 472-480.
25. CORTES, J.E., M. TALPAZ, S. O'BRIEN, et al. 2002. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily [Abstract]. Blood 100: 95a.
26. ZANDER, A., T. ZABELINA, H. RENGES, et al. 2004. Pre-treatment with Glivec increases transplant-related mortality after allogeneic transplant [Abstract]. Bone Marrow Transplant 33 (Suppl. 1): 60.
27. TIRIBELLI, M., L. MARIN, E. CALISTRI, et al. 2004. Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias. Bone Marrow Transplant 34: 827-828.
28. SHIMONI, A., N. KROGER, A.R. ZANDER, et al. 2003. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 17: 290-297.
29. BARTOLOVIC, K., S. BALABANOV, U. HARTMANN, et al. 2004. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103: 523-529.
30. FANG, G., C.N. KIM, C.L. PERKINS, et al. 2000. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96: 2246-2253.
31. HOLTZ, M.S., M.L. SLOVAK, F. ZHANG, et al. 2002. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99: 3792-3800.
32. HORITA, M., E.J. ANDREU, A. BENITO, et al. 2000. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 191: 977-984.
33. SILVER, R.T. 2003. Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythemia vera. Leukemia 17: 1186-1187.
34. JONES, C.M. & T.M. DICKINSON. 2003. Polycythemia vera responds to imatinib mesylate. Am. J. Med. Sci. 325: 149-152.
35. OEHLER, L., E. JAEGER, A. ESER, et al. 2003. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood 102: 2240-2242.
36. HOEPFL, J., C. MIETHING, R. GRUNDLER, et al. 2002. Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia 16: 1584-1588.
37. null mice [Abstract]. Blood 100: 302a.
38. GRAHAM, S.M., H.G. JORGENSEN, E. ALLAN, et al. 2002. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
39. BHATIA, R., M. HOLTZ, N. NIU, et al. 2003. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701-4707.
40. MARLEY, S.B., M.W. DEININGER, R.J. DAVIDSON, et al. 2000. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp. Hematol. 28: 551-557.
41. DEWAR, A.L., R.M. DOMASCHENZ, K.V. DOHERTY, et al. 2003. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 17: 1713-1721.
42. BLECHMAN, J.M., S. LEV, J. BARG, et al. 1995. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80: 103-113.
43. ROSTI, V., G. BERGAMASCHI, C. LUCOTTI, et al. 1995. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood 86: 3387-3393.
44. HUI, C.H., K.Y. GOH, D. WHITE, et al 2003. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 17: 821-828.
45. CAUX, C., C. DEZUTTER-DAMBUYANT, D. SCHMITT, et al. 1992. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360: 258-261.
46. BROSSART, P., S. WIRTHS, W. BRUGGER, et al. 2001. Dendritic cells in cancer vaccines. Exp. Hematol. 29: 1247-1255.
47. CELLA, M., F. SALLUSTO, & A. LANZAVECCHIA. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9: 10-16.
48. MARASKOVSKY, E., K. BRASEL, M. TEEPE, et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184: 1953-1962.
49. SALLUSTO, F. & A. LANZAVECCHIA. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179: 1109-1118.
50. SIENA, S., M. DI NICOLA, M. BREGNI, et al. 1995. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp. Hematol. 23: 1463-1471.
51. YOUNG, J.W., P. SZABOLCS & M.A. MOORE. 1995. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J. Exp. Med. 182: 1111-1119.
52. ZHOU, L.J. & T.F. TEDDER. 1996. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA 93: 2588-2592.
53. APPEL, S., A.M. BOEHMLER, F. GRUNEBACH, et al. 2004. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103: 538-544.
54. GHOSH, S., M.J. MAY & E.B. KOPP. 1998. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225-260.
55. RESCIGNO, M., M. MARTINO, C.L. SUTHERLAND, et al. 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188: 2175-2180.
56. NEUMANN, M., H. FRIES, C. SCHEICHER, et al. 2000. Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 95: 277-285.
57. WEIH, F., D. CARRASCO, S.K. DURHAM, et al. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80: 331-340.
58. OYAMA, T., S. RAN, T. ISHIDA, et al. 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160: 1224-1232.
59. AMMON, C., K. MONDAL, R. ANDREESEN, et al. 2000. Differential expression of the transcription factor NF-kappaB during human mononuclear phagocyte differentiation to macrophages and dendritic cells. Biochem. Biophys. Res. Commun. 268: 99-105.
60. WU, L., A. D'AMICO, K.D. WINKEL, et al. 1998. RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 9: 839-847.
61. PETTIT, A.R., C. QUINN, K.P. MACDONALD, et al. 1997. Nuclear localization of RelB is associated with effective antigen-presenting cell function. J. Immunol. 159: 3681-3691.
62. BURKLY, L., C. HESSION, L. OGATA, et al. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373: 531-536.
63. OUAAZ, F., J. ARRON, Y. ZHENG, et al. 2002. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16: 257-270.
64. TAIEB, J., K. MARUYAMA, C. BORG, et al. 2004. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103: 1966-1967.
65. BHATTACHARYYA, S., P. SEN, M. WALLET, et al. 2004. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and IB kinase activity. Blood 104: 1100-1109.
66. GUSTIN, J.A., O.N. OZES, H. AKCA, et al. 2004. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J. Biol. Chem. 279: 1615-1620.
67. OZES, O.N., L.D. MAYO, J.A. GUSTIN, et al. 1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
68. MANNA, S.K. & B.B. AGGARWAL. 2000. Wortmannin inhibits activation of nuclear transcription factors NF-kappaB and activated protein-1 induced by lipopolysaccharide and phorbol ester. FEBS Lett. 473: 113-118.
69. XIE, P., D.D. BROWNING, N. HAY, et al. 2000. Activation of NF-kappa B by bradykinin through a Galpha(q)- and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. J. Biol. Chem. 275: 24907-24914.
70. SATO, N., M. NARITA, M. TAKAHASHI, et al. 2003. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol. Oncol. 21: 67-75.
71. DIETZ, A.B., L. SOUAN, G.J. KNUTSON, et al. 2004. Imatinib mesylate inhibits T cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099.
72. WANG, H. , F. CHENG, A. CUENCA, et al. 2004. Imatinib mesylate (STI-571) enhances antigen presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105: 1135-1143.